RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 48 filers reported holding RECRO PHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $440,319 | +17.1% | 938,847 | +174.5% | 0.05% | +24.3% |
| Q2 2023 | $376,160 | -17.9% | 341,964 | -11.2% | 0.04% | -21.3% |
| Q1 2023 | $458,432 | -49.4% | 385,237 | -36.6% | 0.05% | -58.4% |
| Q4 2022 | $905,422 | +129.8% | 607,666 | +151.7% | 0.11% | +105.5% |
| Q3 2022 | $394,000 | +99.0% | 241,472 | -2.8% | 0.06% | +111.5% |
| Q2 2022 | $198,000 | -58.8% | 248,472 | -6.9% | 0.03% | -52.7% |
| Q1 2022 | $481,000 | -7.7% | 266,972 | -12.3% | 0.06% | -3.5% |
| Q4 2021 | $521,000 | +644.3% | 304,533 | +793.0% | 0.06% | +5600.0% |
| Q3 2021 | $70,000 | -11.4% | 34,103 | -0.9% | 0.00% | -90.0% |
| Q2 2021 | $79,000 | -76.1% | 34,403 | -70.9% | 0.01% | -76.7% |
| Q1 2021 | $330,000 | +148.1% | 118,232 | +153.3% | 0.04% | +126.3% |
| Q4 2020 | $133,000 | -36.1% | 46,682 | +83.5% | 0.02% | -60.4% |
| Q1 2020 | $208,000 | – | 25,438 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 2,202,420 | $6,145,000 | 3.11% |
| Samjo Capital LLC | 560,000 | $1,562,000 | 1.16% |
| MAK CAPITAL ONE LLC | 1,224,264 | $3,416,000 | 0.81% |
| Cowen Prime Services LLC | 470,500 | $1,313,000 | 0.50% |
| Portolan Capital Management | 1,957,283 | $5,461,000 | 0.43% |
| Parkman Healthcare Partners LLC | 601,967 | $1,679,000 | 0.39% |
| Rubric Capital Management LP | 1,076,587 | $3,004,000 | 0.18% |
| Frontier Wealth Management LLC | 49,112 | $2,142,000 | 0.16% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 466,992 | $1,303,000 | 0.16% |
| AWM Investment Company, Inc. | 391,304 | $1,092,000 | 0.12% |